GVR Report cover Latent Tuberculosis Infection Detection Market Size, Share & Trends Report

Latent Tuberculosis Infection Detection Market Size, Share & Trends Analysis Report By Test Type, By Application, End-user, By Region, And Segment Forecasts, 2022 To 2030

  • Report ID: GVR453389
  • Number of Pages: 0
  • Format: Electronic (PDF)

The growth of the latent tuberculosis infection detection market is attributed to the increasing risk of developing active TB from latent tuberculosis infection (LTBI), rise in funding to manage disease treatment, increasing government initiatives, and rise in awareness campaigns conducted by non-government bodies and market players. According to the WHO, around 10 million individuals fell ill with active tuberculosis, worldwide. Moreover, people infected with TB bacteria have a 5-10% lifetime risk of developing the disease. The high risk of progressing TB disease is increasing the adoption of testing for latent TB infections.

Moreover, the Global Plan to End TB estimated that around USD 13 billion was required in 2020 for tuberculosis prevention, diagnosis, and treatment services rising to USD 15.5 billion in 2022 in the LMICs. The Global Fund to Fight AIDS, tuberculosis, and malaria is the main source of funding for the management of tuberculosis disease, with a contribution of 75% of total international funding in 2020. Moreover, government initiatives such as the Sustainable Development Goals (SDGs) aimed to end the TB epidemic by 2030.

The market is segmented based on test type, application, and end user. Among the test type segment, the tuberculin skin test (TST) segment held the largest market share in 2021, owing to the high market penetration rate of this test type, increasing awareness about tuberculosis infection, and the cost-effectiveness of the test. However,gamma interferon released assay (IGRA) segment is expected to grow at a faster rate in the forecast period due to the increasing adoption of the technologically advanced testing method.

North America dominated the global LTBI detection market in 2021 due to high adoption of testing, government favorable initiatives, high funding for tuberculosis management, and rising awareness about early diagnosis of infection. For instance, the U.S. is one of the largest donors to global TB control efforts. In 2021, the U.S. funded around USD 332 million for global tuberculosis efforts. Moreover, since May 2022, the CDC has removed the requirement of annual screening, if certain conditions are met. However, the Asia Pacific is expected to grow at the fastest rate in the forecast period due to the high infection rate in developing countries and the increasing adoption of testing for latent TB infection.

Latent Tuberculosis Infection Detection Market Segmentation

Segments

Details

Test Type

Tuberculin skin test (TST), Interferon gamma released assay (IGRA)

Application

Household contacts with pulmonary TB, PLHIV, Others

End User

Diagnostic laboratories, Hospitals/clinics, Academic & research institutions

Region

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

 

Key players operating in the LTBI market include QIAGEN; Oxford Immunotec USA, Inc.; F. Hoffmann-La Roche Ltd.; Sanofi; Abbott; bioMérieux SA; and Becton, Dickinson, and Company. Key players are expanding their product availability by introducing their products in overseas countries to increase their market share over the forecast period. For instance, in February 2022, QIAGEN received approval for its QuantiFERON tuberculosis testing solution in china. It is expected to increase the company’s market share in the coming years.

gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.